News & Insights
Stay up to date on PsychoGenics’ latest research, press releases, and industry developments in preclinical drug discovery. Combine our expertise with yours to spark the translational power of your next CNS breakthrough.
Filters
Filters
Therapeutic Areas
In Vivo AI Platforms
Mental Illness
Neurodegenerative Disorders
Neurodevelopmental Disorders
Neuromuscular Disorders
Pain
Sleep & Seizure Disorders
Rare CNS Disorders
Traumatic Brain Injury
Specific Disorders
Apply Filters
Filters
PUBLICATION
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease.
February 15, 2011
PUBLICATION
Histopathological and neurological features of Atg4b knockout mice.
January 29, 2011
PUBLICATION
Dissociation between Duration of Action in the Forced Swim test in Mice and Nicotinic Acetylcholine Receptor Occupancy with Sazetidine, Varenicline, and 5-I-A85380.
January 15, 2011
PUBLICATION
The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
November 29, 2010
PUBLICATION
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments.
August 29, 2010
PUBLICATION
The Novel triple reuptake inhibitor JZAD-IV-22 exhibits an Antidepressant Pharmacological profile without Locomotor Stimulant or Sensitization Properties.
June 29, 2010
PUBLICATION
Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.
June 27, 2010
PUBLICATION
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
June 25, 2010
PUBLICATION
Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline.
May 29, 2010